Equity Compensation Plans

12 Months Ended

Dec. 31, 2019

Share-based Payment Arrangement [Abstract]

As of December 31, 2019, the Company’s equity compensation plans consisted of the 2003 Stock Incentive Compensation Plan (the “2003 Plan”) and the 2012 Stock Incentive Plan (the “2012 Plan” and together with the 2003 Plan, the “Plans”) under which incentive and non-qualified stock options and time and performance based restricted shares have been granted to employees and directors from authorized but unissued shares of common stock or treasury shares. The 2003 Plan is not active, but continues to govern all outstanding awards granted under the plan until the awards themselves are exercised or terminate in accordance with their terms. The 2012 Plan, approved by stockholders on April 27, 2012, authorized 1,750,000 shares of common stock for awards. The 2012 Plan also authorizes an additional 1,200,000 shares of common stock to the extent awards granted under prior stock plans that were outstanding as of April 27, 2012 are forfeited. The 2012 Plan provides for the following type of awards: options, restricted stock, restricted stock units and other stock-based awards. During the fourth quarter of 2019, additional shares of common stock were issued pursuant to separate inducement share agreements with two individuals as material inducement to their employment with the Company (the "Inducement Grants"). The Inducement Grants awarded stock options and restricted stock to the two individuals. Amounts shown below are inclusive of the Plans and the Inducement Grants.

The Company accounts for the expense of all share-based compensation by measuring the awards at fair value on the date of grant. The Company recognizes expense on a straight-line basis over the vesting period of the entire award. Options issued by the Company under its stock option plans have a term of ten years and generally vest ratably over a period of three to four years. Time-based restricted stock grants are expensed over the vesting period of the award, which is typically two to four years. The number of performance based restricted shares that vest or forfeit depend upon achievement of certain targets during the performance period. The Company accounts for forfeitures as they occur. Compensation expense for performance based awards granted prior to December 2018 is recorded based upon the service period and management’s assessment of the probability of achieving the performance goals and will be adjusted based upon actual achievement. In December 2018, the performance metric changed to a 3-year relative Total Shareholder Return (TSR) compared to S&P 600 industrial index instead of a pre-established earning-per-share target to better align compensation to the long-term interest of shareholders. Stock options issued under the current plan must have an exercise price that may not be less than the fair market value of the Company’s common stock on the date of grant. The Plans provide for automatic acceleration of vesting in the event of a change in control of the Company.

The Company incurred compensation expense of $2.9 million, $2.1 million, and $4.3 million for the years ended December 31, 2019, 2018, and 2017, respectively, for all stock-based compensation plans, including restricted stock awards. No compensation costs were capitalized as part of inventory. The associated tax benefit realized was $0.2 million, $1.3 million, and $4.0 million for the years ended December 31, 2019, 2018, and 2017, respectively.

Stock Options

The fair value of each option granted was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions for the years ended December 31:



	2019		2018		2017
Risk-free interest rate	1.7	%	2.7	%	2.2	%
Expected life	5.3 years		5.5 years		5.5 years
Expected volatility	37	%	34	%	33	%
Expected dividend yield	—	%	—	%	—	%

The following is a summary of the option activity as of December 31, 2019 and changes during the year then ended:



In thousands except per share amounts and years
	Shares	Weighted-Average Exercise Price		Weighted- Average Remaining Contractual Term (years)	Aggregate Intrinsic Value
Outstanding at December 31, 2018	623	$	30.14
Granted	242	$	19.35
Exercised	(40)	$	11.47
Forfeited/Cancelled	(142)	$	31.36
Outstanding at December 31, 2019	683	$	27.15	7.9	$	688
Options exercisable at December 31, 2019	318	$	33.01	6.1	$	372
Unvested at December 31, 2019	365	$	22.04	3.0	$	316

The Company granted 242,592, 245,830, and 99,840 stock options during 2019, 2018, and 2017, respectively. The weighted-average grant-date fair value of options granted during the years 2019, 2018, and 2017 was $19.35, $21.49, and $17.91, respectively. There were 40,147 options exercised in 2019, 54,316 options exercised in 2018, and 90,897 options exercised in 2017. The intrinsic value for options exercised during 2019 was $0.4 million and the associated tax benefit realized from stock options exercised was $0.1 million. The total intrinsic value for options exercised during 2018 was $1.4 million and the associated tax benefit realized from stock options exercised was $0.3 million. The total intrinsic value for options exercised during 2017 was $3.6 million and the associated tax benefit realized from stock options exercised was $1.1 million. The amount of cash received from the exercise of stock options was $0.4 million in 2019, $0.9 million in 2018, and $1.3 million in 2017. At December 31, 2019, the total unrecognized compensation cost related to non-vested stock option awards was approximately $2.7 million, with a weighted average expected amortization period of 3.0 years.

Restricted Stock

The following is a summary of the Company’s unvested restricted shares for the year ended and as of December 31, 2019:



In thousands except per share amounts
Outstanding Restricted Shares	Shares	Weighted-Average Grant-Date Fair Value
Nonvested at December 31, 2018	304	$	37.02
Granted	157	$	20.96
Vested	(23)	$	56.45
Forfeited/Cancelled	(150)	$	38.07
Nonvested at December 31, 2019	288	$	26.13

Restricted stock includes both performance-based and time-based awards. Compensation for restricted stock is recorded based on the fair market value of the stock on the grant date and amortized to expense over the vesting period of the award. The Company granted 59,566, 99,560, and 52,595 shares of performance-based restricted stock during 2019, 2018, and 2017, respectively. The Company granted 97,803 shares of time-based restricted stock in 2019, 71,516 shares in 2018, and 22,700 in 2017. The Company granted 1,245, and 485 of time-based restricted stock units in 2018 and 2017, respectively. The weighted average fair value per share of restricted stock granted was $20.96, $25.19, and $45.18 during 2019, 2018, and 2017, respectively. During 2019, 2018, and 2017, respectively, there were 150,365, 8,440 and 14,045 shares of restricted stock forfeited. The fair value of awards for which restrictions lapsed during the years ended December 31, 2019, 2018, and 2017 was $0.5 million, $3.2 million, and $8.0 million, respectively. At December 31, 2019, the total unrecognized compensation cost related to non-vested restricted stock awards was approximately $4.5 million, with a weighted average expected amortization period of 2.4 years.

Stock Repurchases

During the year ended December 31, 2019, the Company acquired 7,122 shares of common stock valued at $0.2 million, through withholding, pursuant to provisions in agreements with recipients of restricted stock granted under the Company's equity compensation plans, which provide for the Company to withhold the number of shares having fair value equal to each recipient's tax withholding due.